Angiex
Biotechnology company developing a platform of nuclear-delivered antibody-drug conjugates (ND-ADCs) that exploit TM4SF1-mediated internalization to deliver therapeutic payloads to the nucleus of tumor cells and tumor-associated endothelium. Lead candidate is an ADC in Phase 1 clinical development for solid tumors. The company performs preclinical in vitro and in vivo pharmacology, safety studies in non-human primates, and multi-site early-phase clinical trials while partnering with CDMOs and diagnostic providers for manufacturing and response monitoring.
Industries
Nr. of Employees
small (1-50)
Patents
Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same
US-12428477-B2
View Details
Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same
US-12428477-B2
View DetailsProducts
AGX101
A TM4SF1-directed antibody-drug conjugate designed to deliver a tubulin inhibitor payload to TM4SF1-expressing tumor cells and tumor-associated endothelium via nuclear delivery; currently in Phase 1 clinical evaluation for advanced solid tumors.
Nuclear-Delivered Antibody-Drug Conjugates
First-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) designed to target TM4SF1 in solid tumors, attacking tumor cells, tumor blood vessels, and cancer lethality hallmarks.
AGX101
A TM4SF1-directed antibody-drug conjugate designed to deliver a tubulin inhibitor payload to TM4SF1-expressing tumor cells and tumor-associated endothelium via nuclear delivery; currently in Phase 1 clinical evaluation for advanced solid tumors.
Nuclear-Delivered Antibody-Drug Conjugates
First-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) designed to target TM4SF1 in solid tumors, attacking tumor cells, tumor blood vessels, and cancer lethality hallmarks.
Services
Partnerships with clinical sites, diagnostic providers, and CDMOs to support clinical trial conduct, manufacturing of clinical supplies, and longitudinal biomarker monitoring.
Partnerships with clinical sites, diagnostic providers, and CDMOs to support clinical trial conduct, manufacturing of clinical supplies, and longitudinal biomarker monitoring.
Expertise Areas
- Antibody-drug conjugate development
- ADC conjugation chemistry and DAR control
- Tumor vascular biology and angiogenesis
- Preclinical in vitro and in vivo pharmacology
Key Technologies
- Antibody-drug conjugates (ADC)
- Site-specific conjugation
- Microtubule-mediated nuclear internalization
- Tubulin/microtubule inhibitor payloads
News & Updates
Collaboration to include longitudinal circulating tumor DNA testing to explore molecular response monitoring during investigational ADC treatment.
Preclinical in vivo data presented at AACR showing combination activity with PD-1 and CTLA-4 inhibitors and effects on tumor microenvironment.
Equity financings completed to support dose-escalation and expansion components of Phase 1 clinical development.
Announcement of the first patient dosed in the Phase 1 clinical trial of the lead ADC candidate.
Regulatory clearance of an Investigational New Drug application enabling first-in-human studies.
Presentation of preclinical data at AACR and publication of abstracts supporting the ADC program and nuclear delivery platform.
Collaboration to include longitudinal circulating tumor DNA testing to explore molecular response monitoring during investigational ADC treatment.
Preclinical in vivo data presented at AACR showing combination activity with PD-1 and CTLA-4 inhibitors and effects on tumor microenvironment.
Equity financings completed to support dose-escalation and expansion components of Phase 1 clinical development.
Announcement of the first patient dosed in the Phase 1 clinical trial of the lead ADC candidate.
Regulatory clearance of an Investigational New Drug application enabling first-in-human studies.
Presentation of preclinical data at AACR and publication of abstracts supporting the ADC program and nuclear delivery platform.